Supplementary Table 1.
Evaluation of Reactogenity (Local and Systemic Symptoms) After SARS-CoV-2 Vaccination in LT Patients and Health Care Workers
| Overall LT patients (n = 492) | Negative serology to SARS-CoV-2 vaccination (n = 108) | Positive serology to SARS-CoV-2 vaccination (n = 336) | Previous SARS-CoV-2 infection (n = 48) | Health care workers (n = 307) | |
|---|---|---|---|---|---|
| Reported local side effects | |||||
| After 1st dose | |||||
| Pain | 368 | 76 | 257 | 35 | 287 |
| Mild | 274 | 45 | 206 | 23 | 231 |
| Moderate | 93 | 31 | 50 | 12 | 56 |
| Severe | 1 | 0 | 1 | 0 | 0 |
| Redness | 44 | 12 | 27 | 5 | 24 |
| Mild | 31 | 9 | 18 | 4 | 18 |
| Moderate | 13 | 3 | 9 | 1 | 6 |
| Severe | 0 | 0 | 0 | 0 | 0 |
| Swelling | 31 | 6 | 22 | 3 | 32 |
| Mild | 19 | 2 | 14 | 3 | 28 |
| Moderate | 12 | 4 | 8 | 0 | 4 |
| Severe | 0 | 0 | 0 | 0 | 0 |
| Regional lymphadenopathy | 1 | 0 | 1 | 0 | 0 |
| After 2nd dose | |||||
| Pain | 301 | 52 | 226 | 23 | 271 |
| Mild | 223 | 35 | 176 | 12 | 243 |
| Moderate | 78 | 17 | 50 | 11 | 27 |
| Severe | 0 | 0 | 0 | 0 | 0 |
| Redness | 35 | 8 | 21 | 6 | 21 |
| Mild | 25 | 5 | 16 | 4 | 19 |
| Moderate | 10 | 3 | 5 | 2 | 2 |
| Severe | 0 | 0 | 0 | 0 | 0 |
| Swelling | 27 | 4 | 19 | 4 | 24 |
| Mild | 19 | 4 | 12 | 3 | 19 |
| Moderate | 8 | 0 | 7 | 1 | 5 |
| Severe | 0 | 0 | 0 | 0 | 0 |
| Regional lymphadenopathy | 0 | 0 | 0 | 0 | 0 |
| Reported systemic side effects | |||||
| After 1st dose | |||||
| Fatigue | 216 | 51 | 147 | 18 | 259 |
| Mild | 104 | 23 | 70 | 11 | 184 |
| Moderate | 89 | 22 | 61 | 6 | 63 |
| Severe | 23 | 6 | 16 | 1 | 12 |
| Myalgia/arthralgia | 103 | 21 | 73 | 9 | 87 |
| Mild | 64 | 12 | 47 | 5 | 71 |
| Moderate | 36 | 8 | 24 | 4 | 15 |
| Severe | 3 | 1 | 2 | 0 | 1 |
| Headache | 185 | 32 | 129 | 24 | 174 |
| Mild | 140 | 23 | 98 | 19 | 135 |
| Moderate | 44 | 9 | 30 | 5 | 39 |
| Severe | 1 | 0 | 1 | 0 | 0 |
| Fever/chills | 63 | 12 | 46 | 5 | 41 |
| Mild | 42 | 7 | 32 | 3 | 28 |
| Moderate | 19 | 4 | 13 | 2 | 12 |
| Severe | 2 | 1 | 1 | 0 | 1 |
| Nausea/vomiting | 3 | 0 | 2 | 1 | 1 |
| Diarrhea | 8 | 2 | 4 | 2 | 2 |
| After 2nd dose | |||||
| Fatigue | 161 | 43 | 99 | 19 | 201 |
| Mild | 57 | 19 | 33 | 5 | 123 |
| Moderate | 74 | 13 | 51 | 10 | 75 |
| Severe | 30 | 11 | 15 | 4 | 3 |
| Myalgia/arthralgia | 105 | 20 | 74 | 11 | 74 |
| Mild | 53 | 8 | 40 | 5 | 61 |
| Moderate | 48 | 11 | 31 | 6 | 13 |
| Severe | 4 | 1 | 3 | 0 | 0 |
| Headache | 207 | 41 | 140 | 26 | 171 |
| Mild | 102 | 17 | 74 | 11 | 138 |
| Moderate | 102 | 23 | 64 | 15 | 33 |
| Severe | 3 | 1 | 2 | 0 | 0 |
| Fever/chills | 71 | 14 | 50 | 7 | 58 |
| Mild | 29 | 4 | 23 | 2 | 34 |
| Moderate | 39 | 9 | 25 | 5 | 23 |
| Severe | 3 | 1 | 2 | 0 | 1 |
| Nausea/vomiting | 1 | 0 | 1 | 0 | 0 |
| Diarrhea | 4 | 1 | 2 | 1 | 1 |
Note: Data are presented as number.
LT, Liver transplant; SARS-CoV 2, severe acute respiratory syndrome coronavirus 2.